Cargando…

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy

Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of (99m)Tc-mercaptoacetyltriglycine ((99m)Tc-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Rudolf A., Beykan, Seval, Higuchi, Takahiro, Lückerath, Katharina, Weich, Alexander, Scheurlen, Michael, Bluemel, Christina, Herrmann, Ken, Buck, Andreas K., Lassmann, Michael, Lapa, Constantin, Hänscheid, Heribert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173054/ https://www.ncbi.nlm.nih.gov/pubmed/27259246 http://dx.doi.org/10.18632/oncotarget.9775

Ejemplares similares

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
por: Beykan, Seval, et al.
Publicado: (2019)

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
por: Beykan, Seval, et al.
Publicado: (2016)

Biokinetics, dosimetry, and radiation risk in infants after (99m)Tc-MAG3 scans
por: Soares Machado, J., et al.
Publicado: (2018)

DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy
por: Eberlein, Uta, et al.
Publicado: (2015)

Correction to: Biokinetics, dosimetry and radiation risk in infants after (99m)Tc-MAG3 scans
por: Soares Machado, J., et al.
Publicado: (2021)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on (99m)Tc-Octreotide and posttherapeutic (177)Lu-DOTA-TATE scans
por: Amoui, Mahasti, et al.
Publicado: (2021)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

(177)Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α(1)-Microglobulin (A1M), Including Kidney Damage Assessment Using (99m)Tc-MAG3 Imaging
por: Kristiansson, Amanda, et al.
Publicado: (2021)

DNA damage in blood leucocytes of prostate cancer patients during therapy with (177)Lu-PSMA
por: Schumann, Sarah, et al.
Publicado: (2019)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Head to head comparison of [(99m)Tc]Tc(CO)(3)(NTA) and [(99m)Tc]Tc-MAG3 in patients with suspected obstruction
por: Taylor, Andrew T., et al.
Publicado: (2021)

Poor Tc-99m dimercaptosuccinic acid uptake, re-evaluation with Tc-99m MAG3 scintigraphy in Lowe syndrome
por: Koca, Gokhan, et al.
Publicado: (2011)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

Jaffe–Campanacci syndrome: Any role for (99m)Tc-methylene diphosphonate bone and (99m)Tc-octreotide scans for evaluation of the disorder?
por: Qutbi, Mohsen, et al.
Publicado: (2019)

Patient-specific dosimetry of (99m)Tc-HYNIC-Tyr(3)-Octreotide in children
por: Hou, Xinchi, et al.
Publicado: (2017)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Vesicoureteral Reflux Detected on Post-void Image of (99m)Tc MAG3 Renal Scintigraphy
por: Nizar, Naureen, et al.
Publicado: (2013)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

(99m)Tc-MAG3 Diuretic Renography: Intra- and Inter-Observer Repeatability in the Assessment of Renal Function
por: Sachpekidis, Christos, et al.
Publicado: (2020)

A new two-strip TLC method for the quality control of technetium-99m mercaptoacetyl-triglycine ((99m)Tc-MAG3)
por: Straub, Marietta, et al.
Publicado: (2018)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Assessment of renal function in mice with unilateral ureteral obstruction using (99m)Tc-MAG3 dynamic scintigraphy
por: Tantawy, Mohammed N, et al.
Publicado: (2012)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

Optimization of SPECT/CT imaging protocols for quantitative and qualitative (99m)Tc SPECT
por: Kupitz, Dennis, et al.
Publicado: (2021)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [(177)Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
por: Hartrampf, Philipp E., et al.
Publicado: (2021)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0b8l0poc40ah1dtpqk8nkcv93